These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 15031200)

  • 1. Intravitreal triamcinolone acetonide for exudative age related macular degeneration.
    Wong D; Campbell I; Groenwald C; Lancaster E
    Br J Ophthalmol; 2004 Apr; 88(4):598; author reply 598. PubMed ID: 15031200
    [No Abstract]   [Full Text] [Related]  

  • 2. Intereye difference in exudative age-related macular degeneration with minimally classic or occult subfoveal neovascularization after unilateral intravitreal injection of triamcinolone acetonide.
    Jonas JB; Spandau UH; Harder B; Vossmerbaeumer U; Kamppeter BA
    Am J Ophthalmol; 2005 Jun; 139(6):1073-9. PubMed ID: 15953439
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Triamcinolone for occult exudative age-related macular degeneration.
    Gillies MC; Simpson JM; Zhu M
    Am J Ophthalmol; 2006 Jan; 141(1):228; author reply 228-9. PubMed ID: 16387021
    [No Abstract]   [Full Text] [Related]  

  • 4. Exudative age-related macular degeneration treated by intravitreal triamcinolone acetonide. A prospective comparative nonrandomized study.
    Jonas JB; Degenring RF; Kreissig I; Friedemann T; Akkoyun I
    Eye (Lond); 2005 Feb; 19(2):163-70. PubMed ID: 15218517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intravitreal triamcinolone acetonide for treatment of intraocular oedematous and neovascular diseases.
    Jonas JB
    Acta Ophthalmol Scand; 2005 Dec; 83(6):645-63. PubMed ID: 16396641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal triamcinolone acetonide preceding photodynamic therapy for exudative age-related macular degeneration.
    Roth DB; Kulkarni KM; Walsman S; Modi A
    Ophthalmic Surg Lasers Imaging; 2009; 40(5):467-71. PubMed ID: 19772270
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Follow-up after intravitreal triamcinolone acetonide for exudative age-related macular degeneration.
    Jonas JB; Spandau UH; Kamppeter BA; Harder B
    Eye (Lond); 2007 Mar; 21(3):387-94. PubMed ID: 16410809
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Repeated intravitreal injections of triamcinolone acetonide as treatment of progressive exudative age-related macular degeneration.
    Jonas JB; Kreissig I; Degenring R
    Graefes Arch Clin Exp Ophthalmol; 2002 Oct; 240(10):873-4. PubMed ID: 12530461
    [No Abstract]   [Full Text] [Related]  

  • 9. [Intravitreal application of triamcinolone--our experiences].
    Konjević Pernar S; Vatavuk Z; Bencić G; Pentz A; Mandić Z
    Acta Med Croatica; 2006; 60(2):133-5. PubMed ID: 16848205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective, randomized clinical trial of intravitreal triamcinolone treatment of neovascular age-related macular degeneration: one-year results.
    Lee J; Freeman WR; Azen SP; Chung EJ; Koh HJ
    Retina; 2007; 27(9):1205-13. PubMed ID: 18046226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide.
    Jonas JB; Kreissig I; Spandau UH; Harder B
    Am J Ophthalmol; 2006 Mar; 141(3):579-80. PubMed ID: 16490517
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Intravitreal triamcinolone therapy. New therapeutic alternative for patients with vision-threatening eye diseases].
    Klitgaard TL; Haamann PH; Villumsen JE; Larsen M
    Ugeskr Laeger; 2005 Apr; 167(16):1729-31. PubMed ID: 15898599
    [No Abstract]   [Full Text] [Related]  

  • 13. Infectious and noninfectious endophthalmitis after intravitreal high-dosage triamcinolone acetonide.
    Lorenzo Carrero J; Pérez Flores I; González Barcia M
    Am J Ophthalmol; 2006 Sep; 142(3):529; author reply 529-30. PubMed ID: 16935616
    [No Abstract]   [Full Text] [Related]  

  • 14. Intravitreal triamcinolone as a primary therapy in diabetic macular oedema.
    Ziahosseini K; Fong KC; Horgan SE
    Eye (Lond); 2006 Jul; 20(7):861-2; author reply 862-3. PubMed ID: 16096662
    [No Abstract]   [Full Text] [Related]  

  • 15. Duration of the effect of intravitreal triamcinolone acetonide as treatment for diffuse diabetic macular edema.
    Jonas JB; Degenring RF; Kamppeter BA; Kreissig I; Akkoyun I
    Am J Ophthalmol; 2004 Jul; 138(1):158-60. PubMed ID: 15234306
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum levels of triamcinolone acetonide after intravitreal injection.
    Degenring RF; Jonas JB
    Am J Ophthalmol; 2004 Jun; 137(6):1142-3. PubMed ID: 15183810
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases.
    Jonas JB; Schlichtenbrede F
    Eye (Lond); 2008 Jul; 22(7):869-73. PubMed ID: 17304257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravitreal injection of triamcinolone acetonide and intraocular pressure.
    Hernaez-Ortega MC; Soto-Pedre E
    Acta Ophthalmol; 2008 Sep; 86(6):693; author reply 692-3. PubMed ID: 18752520
    [No Abstract]   [Full Text] [Related]  

  • 19. The effect of intravitreal triamcinolone on foveal edema in exudative macular degeneration.
    Gillies MC; Larsson J
    Am J Ophthalmol; 2007 Jul; 144(1):134-6. PubMed ID: 17601437
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety of intravitreal high-dose reinjections of triamcinolone acetonide.
    Jonas JB; Degenring R; Kreissig I; Akkoyun I
    Am J Ophthalmol; 2004 Dec; 138(6):1054-5. PubMed ID: 15629306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.